Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
NCT00171418
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG:
Tegaserod
Sponsor
Novartis